γμβ μϊελο δςξεγ

ρψβμ πβιωεϊ

 

|
ξϊλεπιν (6,394)
|
αλμ δΰϊψ

μαθιψΰφθν θας ® 250 ξ"β

ων δϊψετδ αΰπβμιϊ: Levetiracetam Teva ® 250 Mg. ξητωιν ϊψετδ ΰηψϊ? λπρε μΰιπγχρ δϊψετεϊ »
αρμ δαψιΰεϊ αρμ δαψιΰεϊ
|
ωϊσ α-

φεψϊ ξϊο

PER OS

ξιπεο

Tablets

ωιξεω αϊψετδ

- Levetiracetam is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy. - Levetiracetam is indicated as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.- Levetiracetam is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patient from 16 years of age with newly diagnosed epilepsy.- Levetiracetam is indicated in the treatment of primary gneralized tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.

ξρτψ ψιωεν

141 43 31958 00

ιφψο

Teva Pharmaceutical Industries Ltd

ϊεχσ ψιωιεο μϊψετδ

08/2014 - 08/2024

δϊλπιν δξετιςιν αΰϊψ ζδ πεςγε μρτχ ΰιπτεψξφιδ λμμιϊ αμαγ.
ΰιπν ξδεειν δξμφδ, ϊημισ μδϊιιςφεϊ ςν ξεξηδ ΰε χαμϊ ιιςευ ψτεΰι.
αωιξεω ΰε φτιιδ απϊεπιν ωαΰϊψ διπκ ξΰωψ ΰϊ ϊπΰι δωιξεω αΰϊψ.
ηεξψ τςιμ ψιλεζ / λξεϊ αιηιγϊ ξιπεο
Levetiracetam 250 MG
ΰψιζδ λξεϊ αΰψιζδ ηιι ξγσ ϊψετϊ ξψων
Blister pvdc/aluminium 30 x TABLETS ηεγωιν 36 λο
Blister pvdc/aluminium 60 x TABLETS ηεγωιν 36 λο

*

*

χιωεψιν ιδτλε αΰετο ΰεθεξθι μμηιφιν
 

αωμιηϊ ϊβεαδ ΰπι ξχαμ ΰϊ ϊπΰι δωιξεω αΰϊψ.

 
δψων μΰϊψ εχαμ ςγλεπιν ιωιψεϊ μγεΰ"μ ωμκ!
 

φψιλϊ χμεψιεϊ

ξδι λξεϊ δχμεψιεϊ μδ ΰϊν ζχεχιν αιεν?
λπρε μξηωαεο »
345 χμεψιεϊ
ςεβϊ βαιπδ θαςεπιϊ ςν τιψεϊ ιςψ
ςεβϊ βαιπδ θαςεπιϊ ξεωμξϊ ξαφχ ωμ ΰβεζι ξμκ, ωχγιν εϊξψιν, εαξιμει ωμ χψν ΰβεζι χωιε μιξεπι ξτπχ εξηιϊ ΰελξπιεϊ ΰε λμ τψι ιςψ ΰηψ ωΰεδαιν